Nu.Q(TM) Vet Pre-Analytical Data to be Presented at the Veterinary Cancer Society Annual Conference in Houston, Texas
Volition Appoints Dr. Phillip Barnes to Board of Directors
Volition Announces Breakthrough in Enrichment of Tumor Nucleosomes
VolitionRx Limited Announces Second Quarter 2019 Financial Results and Business Update
Volition Forms Texas-Based Veterinary Subsidiary and Appoints its Chief Executive Officer
VolitionRx Limited Schedules Second Quarter 2019 Earnings Conference Call and Business Update
Volition Announces Exercise of Warrant to Purchase $4.8 Million in Common Stock
VolitionRx Limited Commences Lung Cancer Clinical Study with Fosun Long March in China
VolitionRx Limited Awarded an Additional $1.4 Million in Non-Dilutive Funding
VolitionRx Limited Announces First Quarter 2019 Financial Results and Business Update
